Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

OBJECTIVES: To evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). METHODS: In an open-label, randomised controlled trial (ORAL Surveillance...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R, Yamaoka, Kunihiro, Chen, Yi-Hsing, Bhatt, Deepak L, Gunay, Levent M, Sugiyama, Naonobu, Connell, Carol A, Wang, Cunshan, Wu, Joseph, Menon, Sujatha, Vranic, Ivana, Gómez-Reino, Juan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933177/
https://www.ncbi.nlm.nih.gov/pubmed/36600185
http://dx.doi.org/10.1136/ard-2022-222543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933177/
https://www.ncbi.nlm.nih.gov/pubmed/36600185
http://dx.doi.org/10.1136/ard-2022-222543

Ejemplares similares